Kura Oncology Officer Proposes Sale of 8,000 Shares
Separately, Brian Powl's prior-three-month sales include 4,345 common shares sold on August 21, 2026, for $51,663.26, identified as 10b5-1 sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. officer Brian Powl reported a proposed sale of 8,000 common shares, with an aggregate market value of $86,080.00. Morgan Stanley Smith Barney LLC is named as the broker. Separately, Brian Powl's prior three-month sales included 4,345 common shares sold on August 21, 2026, for $51,663.26; these are identified as 10b5-1 sales.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Units financial
10b5-1 Sales regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.